Modular tantalum augments have been introduced to manage severe bone defects in hip and knee revision surgery. The porous surfaces of tantalum augments are intended to enhance osseointegration and a number of studies have documented their excellent biocompatibility. However, the characteristics of tantalum augment osseointegration on human ex vivo specimens from re-revision procedures have not been reported so far. Out of a total number of 324 hip and knee revisions with a tantalum augment performed in our institution between 2007 and 2010 four patients had to be re-revised at a mean followup time of 15 months. The causes for re-revision were a periprosthetic acetabular fracture in one, a loosening of a tibial component in one and periprosthetic hip infections in two cases. To characterize osseointegration of the tantalum augments, they were removed during revision surgery and subjected to undecalcified processing. All specimens were analysed by contact radiography, histology (toluidine blue, von Kossa) and quantitative histomorphometry.Introduction
Methods
Statistical analyses were performed using statistical software. Probability of Type I error was set to 5% (alpha=0.05).
Osteonecrosis was found in 81 (97.6%) hips revised after fracture (p<
.0001). The vertical size of avascular necrosis in hips after acute postnecrotic fracture (21.1mm±8.5) was bigger (p<
.0001) than in both chronic (7.3mm±7.3) and acute mechanic (0.9 mm±1.2) fractures. Even though 33 (66.0%) of 50 patients with acute postnecrotic fracture were men (p=.0237), no significant differences between males and females were found with respect to age of patients (p=.3445) or duration of prosthesis implantation (p=.1232).
The proposed classification may help to understand causes of periprosthetic fractures after hip resurfacing arthroplasty.
The Gorham-Stout Syndrome (Gorham’s massive osteolysis) is a rare condition in which spontaneous, progressive resorption of bone occurs. The aetiology is poorly understood. We report six cases of the condition and present evidence that osteolysis is due to an increased number of stimulated osteoclasts. This suggests that early potent antiresorptive therapy such as with calcitonin or bisphosphonates may prevent local progressive osteolysis.